LCTX vs VCEL
LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies. VCEL: Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and Epicel for severe burns.
Side-by-side fundamentals
| Metric | LCTX | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.03 | $45.32 | |
| Market cap as of 2026-07-31 | $275M | $2.3B | |
| P/E as of 2026-07-31 | n/a | 117.19 | |
| PEG as of 2026-07-31 | -0.01 | 0.12 | LCTX lower |
| Net margin as of 2026-07-31 | -431.2% | +7.3% | VCEL higher |
| Gross margin as of 2026-07-31 | +94.1% | +74.8% | LCTX higher |
| Operating margin as of 2026-07-31 | -256.5% | +5.4% | VCEL higher |
| ROE as of 2026-07-31 | -151.3% | +6.4% | VCEL higher |
| ROA as of 2026-07-31 | -63.3% | +4.6% | VCEL higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | LCTX lower |
| Revenue growth (YoY) as of 2026-07-31 | -37.1% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +18.9% | VCEL higher |
| Beta as of 2026-07-31 | 1.52 | 1.06 | |
| 1-year return as of 2026-07-27 close | -8.8% | +13.0% | VCEL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.